4448-75-3

Basic information

• Product Name: (HYDROXYMETHYL)CYCLOHEPTANE
• Synonyms: Cycloheptylmethanol;(HYDROXYMETHYL)CYCLOHEPTANE;CYCLOHEPTYL CARBINOL;CYCLOHEPTANEMETHANOL
• CAS NO: 4448-75-3
• Molecular Formula: C₈H₁₆O
• Molecular Weight: 128.21
• EINECS: 224-691-5
• Mol File: 4448-75-3.mol
• Article Data: 28

Chemical Properties

• Boiling Point: 213°C 714mm
• Flash Point: 92.8 °C
• Appearance: /
• Density: 0.898 g/cm³
• Vapor Pressure: 0.0328mmHg at 25°C
• Refractive Index: 1.451
• PKA: 15.05±0.10(Predicted)
• CAS DataBase Reference: (HYDROXYMETHYL)CYCLOHEPTANE(CAS DataBase Reference)
• NIST Chemistry Reference: (HYDROXYMETHYL)CYCLOHEPTANE(4448-75-3)
• EPA Substance Registry System: (HYDROXYMETHYL)CYCLOHEPTANE(4448-75-3)

Safety Data

• Statements: 36/37/38
• Safety Statements: 26-36/37/39
• Hazardous Substances Data: 4448-75-3(Hazardous Substances Data)

Usage

General Description

(Hydroxymethyl)cycloheptane is a chemical compound that belongs to the class of organic compounds known as cycloalkanes. Cycloalkanes are alkanes featuring one or more rings of carbon atoms. Within this collection of compounds, (hydroxymethyl)cycloheptane is particularly unique. The term "hydroxymethyl" refers to the presence of a hydroxyl group (-OH) and a methyl group (-CH3) as part of the molecular structure. The "cycloheptane" portion of the molecule refers to its basic core structure, a ring of seven carbon atoms. (HYDROXYMETHYL)CYCLOHEPTANE is generally used in the field of organic chemistry for various synthesis processes.

InChI:InChI=1/C8H16O/c9-7-8-5-3-1-2-4-6-8/h8-9H,1-7H2

Upstream product

• 1460-16-8 cycloheptanoic acid 
• 26600-50-0 acetic acid cycloheptylmethyl ester 
• 4277-29-6 cycloheptanecarboxaldehyde 
• 766-77-8 Dimethylphenylsilane 
• 1375389-97-1 C₁₄H₂₇O₅P 
• 60433-00-3 methyl cycloheptanecarboxylate 
• 201230-82-2 carbon monoxide 
• 628-92-2 Cycloheptene 
• 1614-73-9 4-cycloheptene-1-carboxylic acid 
• 2505-03-5 methylenecycloheptane 
• 50-00-0 formaldehyd 
• 917-64-6 methyl magnesium iodide 
• 502-42-1 cycloheptanone 
• 78371-03-6 Benzyloxymethyl-cycloheptane 

Downstream Products

• 3814-32-2 1-(bromomethyl)cycloheptane 
• 931-88-4 cis-Cyclooctene 
• 40213-25-0 <4-Brom-benzolsulfonyl-oxymethyl>-cycloheptan, Cycloheptanemethyl-brosylate 
• 191664-06-9 4-Chloro-benzenesulfonic acid cycloheptylmethyl ester 
• 16472-98-3 cycloheptylmethyl 4-methylbenzenesulfonate 
• 226723-96-2 1--4,8-N-(2-mesitylenesulfonyl)-11--4,8-diazaundecane 
• 1098107-83-5 C₁₆H₂₁Cl₃O₃S 

Relevant articles and documents

Me3SI-promoted chemoselective deacetylation: a general and mild protocol

A Me3SI-mediated simple and efficient protocol for the chemoselective deprotection of acetyl groups has been developedviaemploying KMnO4as an additive. This chemoselective deacetylation is amenable to a wide range of substrates, tolerating diverse and sensitive functional groups in carbohydrates, amino acids, natural products, heterocycles, and general scaffolds. The protocol is attractive because it uses an environmentally benign reagent system to perform quantitative and clean transformations under ambient conditions.

Production of oxygen-containing alicyclic compounds (by machine translation)

[Problem] to provide, in a one-step reaction synthesizes an alicyclic compound containing oxygen, high yield production of oxygen-containing compound is a cycloaliphatic. [Solution] one or more hydroxy or carbonyl group 2, or a hydroxyl group having the carbon number of 5 or more aliphatic carbonyl group 2 in accordance with one or more oxygen-containing compound, a basic catalyst is brought into contact with an oxygen-containing alicyclic compound by cyclodehydration reaction, oxygen-containing alicyclic compound. [Drawing] no (by machine translation)

COMBINATION TREATMENTS COMPRISING ADMINISTRATION OF IMIDAZOPYRAZINONES

The present invention provides combination treatments comprising administration of compounds that are PDE1 enzyme inhibitors and other compounds useful in the treatment of neurodegenerative disorders such as for example Alzheimer's Disease, Parkinson's Disease or Huntington's Disease. Separate aspects of the invention are directed to the combined use of said compounds for the treatment of neurodegenerative and/or cognitive disorders. The present invention also provides pharmaceutical compositions comprising said PDE1 enzyme inhibitors together with other compounds useful in the treatment of neurodegenerative disorders.